- Home
- RAPT vs PROK Comparison
RAPT vs PROK Comparison
Compare RAPT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | PROK |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.4M | 417.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAPT | PROK |
|---|---|---|
| Price | $35.10 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $57.00 | $7.40 |
| AVG Volume (30 Days) | 433.7K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $956.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.67 | $0.46 |
| 52 Week High | $42.39 | $7.13 |
Technical Indicators
Market Signals| Indicator | RAPT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 55.43 |
| Support Level | $34.38 | $2.33 |
| Resistance Level | $36.92 | $2.59 |
| Average True Range (ATR) | 2.56 | 0.15 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 50.37 | 90.57 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.